Reports
Publicerat: 2019-11-11 15:13:57
CEO’s comments Market Expansion of the product portfolio Strategic initiatives
Financially
The investments EQL Pharma made in its product portfolio in recent years continue to provide good returns. For the second quarter in a row, sales increased by more than 30 percent compared to the same period last year. Quarterly sales are also the company"s best since the company was founded. Through efficient working capital financing, cash liquidity is good despite large continued investments in the product portfolio.
During the quarter, EQL Pharma got its first hospital product approved. The product is approved for sale in Sweden, Denmark, Norway and Finland. Sales of hospital products are through a procurement procedure, a new sales channel for EQL. Over time, EQL will begin to report hospital sales as its own segment, but sales must first reach a relevant size.
EQL Pharma conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in, for example, India and China. Several important products are now approaching submission to the various pharmaceutical authorities.
In addition to the strategic initiative (1) expansion of the product portfolio (see above), the company has also successfully worked with other initiatives (2) improved logistics chain, (3) geographical expansion and (4) unique products. The initiatives are aimed at ensuring long-term and sustainable profitability growth.
For further information, please contact: Phone: +46 (0) 705 – 60 90 00 About EQL Pharma July - September
April - September
Significant events during the second quarter
Significant events after the second quarter
EQL Pharma is one of the eight companies that has been approved from the start and lives up to the requirements set in the segment.
Christer Fåhraeus
CEO, EQL Pharma AB (publ)
Email: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
EQL Pharma AB is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently has 18 niche generics (i.e. generics with little or no competition except for the original medicine) approved on the Swedish and Danish markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2019 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma AB is based in Lund, Sweden, employs 9 people and is listed on Spotlight Stock Market. EQL Pharma AB also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.